Cytek Biosciences (NASDAQ:CTKB) is a life sciences tools company specializing in high-parameter spectral flow cytometry systems and accompanying reagents. The company develops, manufactures and markets instruments designed to enable researchers and clinicians to analyze complex cellular populations with enhanced sensitivity and resolution. Its solutions support workflows in immunology, oncology, cell therapy and other applications requiring multi-color analysis of individual cells.
Founded in 1998 as a research division focused on next-generation cytometry, Cytek Biosciences became an independent entity in the mid-2010s. Headquartered in Fremont, California, the company has expanded its global footprint with offices and technical support teams in Europe and the Asia-Pacific region. Over the years, Cytek has worked closely with leading academic institutions, biotechnology firms and pharmaceutical companies to advance single-cell analysis and accelerate drug discovery.
Key products include the Aurora and Northern Lights spectral flow cytometers, which leverage proprietary optics and fluidics to capture a broader spectrum of fluorescence signals. Complementary reagent kits and the SpectroFlo software platform enable users to design high-dimensional panels, automate data acquisition and perform sophisticated analysis. Cytek also offers customer training, instrument maintenance and assay development services to ensure optimal performance and reproducibility.
The company is led by Chief Executive Officer Luxin Ding, supported by a management team with deep expertise in cytometry, engineering and life sciences. Under this leadership, Cytek Biosciences continues to invest in research and development, expand its product portfolio and forge strategic partnerships aimed at meeting the evolving needs of the global cell analysis market.
